A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 1, 2015, Pages 1-6

  Vanderweide, L A ^a,b   Smith, S M ^c   Trinkley, K E ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

fibromyalgia; serotonin norepinephrine reuptake inhibitor; venlafaxine

Indexed keywords

VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; HUMAN; MCGILL PAIN QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

CYCLOHEXANOLS; FIBROMYALGIA; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84920432817     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12216     Document Type: Review

References (34)

1. Wolfe F, Smythe HA, Yunus MB, et al,. The American College of Rheumatology 1990 critera for the classification of fibromyalgia-report of the Multicenter Criteria Committee. Arthritis Rheum, 1990; 33: 160-172.
2. Wolfe F, Clauw DJ, Fitzcharles MA, et al,. The American College of rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res, 2010; 62: 600-610.
3. Fitzcharles MA, Boulos P,. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology, 2003; 42: 263-267.
4. Buskila D, Neumann L, Sibirski D, Shvartzman P,. Awareness of diagnostic and clinical features of fibromyalgia among family physicians. Fam Pract, 1997; 14: 238-241.
5. Wolfe F, Walitt BT, Hauser W,. What is fibromyalgia, how is it diagnosed, and what does it really mean? Arthritis Care Res, 2014; 66: 969-971.
6. Brill S, Ablin JN, Goor-Aryeh I, et al,. Prevalence of fibromyalgia syndrome in patients referred to a tertiary pain clinic. J Investig Med, 2012; 60: 685-688.
7. Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Lyon JL,. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol, 2006; 12: 124-128.
8. Lawrence RC, Felson DT, Helmick CG, et al,. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum, 2008; 58: 26-35.
9. Knight T, Schaefer C, Chandran A, Zlateva G, Winkelmann A, Perrot S,. Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States. Clinicoecon Outcomes Res, 2013; 5: 171-180.
10. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al,. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manage, 2013; 18: 119-126.
11. Goldenberg DL, Burckhardt C, Crofford L,. Management of fibromyalgia syndrome. J Am Med Assoc, 2004; 292: 2388-2395.
12. Bradley LA,. Pathophysiology of fibromyalgia. Am J Med, 2009; 122: S22-S30.
13. Derry S, Gill D, Phillips T, Moore RA,. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev, 2012; (3): CD008244.
14. Sultan A, Gaskell H, Derry S, Moore RA,. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol, 2008; 8: 29.
15. Choy EHS, Mease PJ, Kajdasz DK, et al,. Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials. Clin Rheumatol, 2009; 28: 1035-1044.
16. Lunn MP, Hughes RA, Wiffen PJ,. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev, 2009; (4): CD007115.
17. Kleinman NL, Sanchez RJ, Lynch WD, Cappelleri JC, Beren IA, Joshi AV,. Health outcomes and costs among employees with fibromyalgia treated with pregabalin vs. standard of care. Pain Pract, 2011; 11: 540-551.
18. Trinkley KE, Nahata MC,. Treatment of irritable bowel syndrome. J Clin Pharm Ther, 2011; 36: 275-282.
19. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE,. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics, 1998; 39: 14-17.
20. Sayar K, Aksu G, Ak I, Tosun M,. Venlafaxine treatment of fibromyalgia. Ann Pharmacother, 2003; 37: 1561-1565.
21. Evren B, Evren C, Guler MH,. Treatment of pain, depressive and anxiety symptoms in fibromyalgia with venlafaxine. Eur Neuropsychopharmacol, 2004; 14: S360.
22. Diaz-Marsa M, Palomares N, Moron MD, et al,. Psychological factors affecting response to antidepressant drugs in fibromyalgia. Psychosomatics, 2011; 52: 237-244.
23. Zijlstra TR, Barendregt PJ, van De Laar MAF,. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum, 2002; 46: S105.
24. American College of Rheumatology (US). Fibromyalgia Impact Questionnaire (FIQ) [Internet]. American College of Rheumatology (US); 2013. Available at: http://www.rheumatology.org/Practice/Clinical/Clinicianresearchers/Outcomes-Instrumentation/Fibromyalgia-Impact-Questionnaire-(FIQ) (accessed 24 August 2014).
25. Detry MA, Lewis RJ,. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. J Am Med Assoc, 2014; 312: 85-86.
26. Perahia DGS, Pritchett YL, Kajdasz DK, et al,. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res, 2008; 42: 22-34.
27. Lenox-Smith AJ, Jiang Q,. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Int Clin Psychopharmacol, 2008; 23: 113-119.
28. Keller MB, Trivedi MH, Thase ME, et al,. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry, 2007; 62: 1371-1379.
29. Taylor D, Lenox-Smith A, Bradley A,. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol, 2013; 3: 151-161.
30. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB,. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol, 2009; 36: 1304-1311.
31. Stauffer ME, Taylor SD, Watson DJ, Peloso PM, Morrison A,. Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale. Int J Inflam, 2011; 2011: 231926.
32. Trivedi MH, Rush AJ, Wisniewski SR, et al,. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am J Psychiatry, 2006; 163: 28-40.
33. Ballenger JC,. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry, 1999; 60 (Suppl 22): 29-34.
34. Hiroe T, Kojima M, Yamamoto I, et al,. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res, 2005; 135: 229-235.